Abstract 1871P
Background
Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of taxane (Paclitaxel, nab-Paclitaxel, Docetaxel). CIPN could reduce long-term quality of life (Blackley et al, 2019) and result in dose delays, reductions or treatment discontinuations. Temperature-controlled hand-foot cooling (Hilotherapy®) prevents CIPN (Oneda et al. 2020&2021, Coolbrandt et al. 2022). Prospectively collected data of 151 breast cancer patients showed that cooling using 1st generation cuffs with 30 minutes post-cooling prevents CIPN ≥ 2° in 93,4% of patients undergoing taxane-based chemotherapy (Schaper et al. in prep.). The development of 2nd generation, combined cooling-compression cuffs, ensures even more effective skin cooling. This raises the question, whether cooling time could be safely reduced.
Methods
We used prophylactic cooling with 2nd generation cuffs as standard of care during chemotherapy without the recommended 30 minutes post-cooling, due to capacity issues, and investigated the efficacy of the 2nd generation cuffs regarding prevention of CIPN through surveys. Patients were stratified according to dosing schedule (q1w vs q3w). Follow-up data will be collected to report the sustainability of the results.
Results
181 breast cancer patients completed their taxane-based chemotherapy using 2nd generation cuffs without post-cooling. 169 (93,4%) patients showed symptoms of CIPN 0-1° and 12 (6,6%) of CIPN 2°. No patient reported grade 3 toxicity. Data collection is still in process and follow-up will be updated to examine the sustainability of the results.
Conclusions
Prophylactic temperature-controlled hand-foot cooling combined with compression (Hilotherapy® 2nd generation) without the recommended 30 minutes post-cooling effectively prevents the development of severe CIPN ≥ 2°.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
ISI e.V. - International Senology Initiativ.
Disclosure
A. Kostara: Non-Financial Interests, Personal and Institutional, Advisory Board, Study Equipment funding: Hilotherm GmbH. All other authors have declared no conflicts of interest.
Resources from the same session
1717TiP - CARE1 pragmatic clinical trial: First line randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma
Presenter: Laurence Albiges
Session: Poster session 12
1822P - Incidence of cachexia and health resource use (HRU) in patients with breast, colorectal, lung, pancreatic, and prostate cancers
Presenter: Imran Ali
Session: Poster session 12
1823P - Significance of skeletal muscle measurement in cancer-associated cachexia screening
Presenter: Lynn Gottmann
Session: Poster session 12
1824P - Sarcopenia in advanced non-small cell lung cancer (NSCLC): Clinical impact and its biological correlates
Presenter: Filippo Dall'Olio
Session: Poster session 12
1826P - Risk factors and incidence of osteoporosis in patients with breast cancer according to gender
Presenter: Chang Ik Yoon
Session: Poster session 12
1827P - Bone health and body composition in prostate cancer: An italian consensus about prevention and management strategies
Presenter: Maria Concetta Cursano
Session: Poster session 12
1828P - A cross-sectional study investigating the current diagnostic & therapeutical approaches to bone metastases (BoM) in patients (pts) with non-small cell lung cancer (NSCLC)
Presenter: Sara Pilotto
Session: Poster session 12
1829P - Nutritional status assessment for patients with common cancer in a cancer hospital of southwest China
Presenter: Huiqing Yu
Session: Poster session 12
Resources:
Abstract
1830P - Comprehensive prognostic effects of inflammatory and nutritional markers to predict survival in women with breast cancer
Presenter: Susanna Hutajulu
Session: Poster session 12
1831P - Obesity and weight variations before treatment, seem to influence weight loss that happens during first-line metastatic lung adenocarcinoma
Presenter: Anthony Tarabay
Session: Poster session 12